Search
trilaciclib (Cosela)
Indications:
- chemotherapy-induced myelosuppression in small cell lung cancer
Contraindications:
- pregnancy
Adverse effects:
- common
- fatigue, headache, hypocalcemia, hypokalemia, hypophosphatemia, increased serum aspartate aminotransferase, pneumonia, pneumonitis
- serious (30%)
- hemorrhage, respiratory failure, thrombosis most common
- other
- drug hypersensitivity
- interstitial lung disease,
Mechanism of action:
- CDK4/CDK6 inhibitor
- reduces bone marrow suppression & risk of neutropenia
General
small inhibitory antineoplastic agent (ib drug)
cyclin-dependent kinase inhibitor (CDKI, CDKN)
References
- Ingram I
New Drug OK'd for Chemo-Induced Myelosuppression in SCLC.
CDK4/6 inhibitor cut the risk for severe neutropenia in small-cell lung cancer patients.
MedPage Today February 13, 2021
https://www.medpagetoday.com/hematologyoncology/lungcancer/91200
- Chustecka Z
First Drug That Protects Against Chemo-Induced Myelosuppression.
Medscape - Feb 15, 2021.
https://www.medscape.com/viewarticle/945820